64 Cu PD 29875
Alternative Names: 64 Cu PD29875Latest Information Update: 16 Jun 2026
At a glance
- Originator PeptiDream
- Class Cyclic peptides; Diagnostic agents; Imaging agents; Macrocyclic compounds; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters; Radionuclide imaging enhancers
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Gastric cancer
- Preclinical Pancreatic cancer
Most Recent Events
- 11 Jun 2026 Phase-0 for Gastric cancer (Diagnosis) in Japan (IV) (jRCTs031250563)
- 01 Feb 2026 Phase-0 for Gastric cancer in Japan (IV) (jRCTs031250563)
- 11 Dec 2025 PeptiDream received approval of clinical research protocol for 64Cu-PD-29875 for the initiation of a clinical trial for Gastric cancer in Japan